Epidemiological evidence links severe or repeated traumatic brain injury (TBI) to the development of Alzheimer's disease (AD). Accumulation of amyloid precursor protein (APP) occurs with high frequency after TBI, particularly in injured axons, and APP may be cleaved to amyloid-b (Ab) peptides playing key pathophysiological roles in AD. We used cerebral microdialysis (MD) to test the hypothesis that interstitial Ab levels are altered following TBI and are related to the injury type, cerebral energy metabolism, age of the patient, and level of consciousness. In the present report, we evaluated 10 mechanically ventilated patients (7 male, 3 female, ages 18-76 years) with a severe TBI, who had intracranial pressure and MD monitoring. Each MD sample was analyzed for hourly routine energy metabolic biomarkers (MD-lactate, MDpyruvate, MD-glucose, and MD-lactate/pyruvate ratio), cellular distress biomarkers (MD-glutamate, MD-glycerol), and MD-urea. The remaining MD samples were analyzed for Ab1-40 (Ab40; n = 765 samples) and Ab1-42 (Ab42; n = 765 samples) in pooled 2 h fractions up to 14 days post-injury, using the Luminex xMAP technique, allowing detection with high temporal resolution of the key Ab peptides Ab40 and Ab42. Data are presented using medians and 25th and 75th percentiles. Both Ab40 and Ab42 were consistently higher in patients with predominately diffuse axonal injury compared with patients with focal TBI at days 1-6 post-injury, Ab42 being significantly increased at 113-116 h post-injury ( p < 0.05). The Ab levels did not correlate with the interstitial energy metabolic situation, age of the patient, or the level of consciousness. These results support that interstitial generation of potentially toxic Ab species may occur following human TBI, particularly related to axonal injury.
Introduction
T raumatic brain injury (TBI) frequently causes longterm sequelae such as cognitive impairment, personality changes, and depression leading to social problems and a reduced quality of life. 1, 2 The chronic disabilities associated with apparently mild TBI, occurring from some blast injuries sustained in the military setting or during sport activities, are also increasingly recognized. 3, 4 Epidemiological evidence links severe or repeated TBI to the development of Alzheimer's disease (AD). [5] [6] [7] [8] [9] [10] Amyloid-b (Ab) plaques, a hallmark pathological finding observed in the brains of AD patients, have been observed in a subset of TBI patients within hours post-injury. 5, 11, 12 The membrane glycoprotein amyloid precursor protein (APP) is synthesized in the neuronal cytoplasm, and accumulates within injured axons following TBI. 5, [13] [14] [15] [16] APP may be proteolytically cleaved by different enzymes including a-secretase, preventing the generation of Ab peptides, or the b-site APP cleaving enzyme 1 (BACE1). BACE1-mediated APP cleavage, combined with c-secretase-mediated cleavage of the remaining APP stub, leads to the generation of amyloid-b (Ab) peptides of various lengths, including the 40 and 42 amino acid long Ab peptides. [17] [18] [19] [20] BACE1 and presenilin, important for Ab generation, have also been found to accumulate in injured and swollen axons post-injury. 21, 22 Although normal neuronal activity can produce Ab via APP processing, 23 these findings make the formation of Ab peptides a likely consequence of axonal injury. Importantly, inhibition of APP b-or c-secretases improves outcome in experimental TBI. 24 As b-and c-secretase-generated Ab forms are released into the interstitial fluid, cerebral microdialysis (MD) is a preferred sampling method for these biomarkers.
One predominant goal of neurocritical care (NCC) is the detection and avoidance of cerebral ischemia. Ischemic brain damage has long been considered a major secondary injury mechanism in TBI. 27 In modern NCC, MD may be used to detect patterns suggestive of ischemia such as an elevated MD lactate/pyruvate ratio (LPR) [28] [29] [30] combined with a reduced interstitial glucose (MD-glc 31, 32 ). In a recent study on 223 TBI patients, MD-LPR and MD-glc were found to be independent predictors of poor outcome. 33 Experimental cerebral ischemia leads to increased APP production and upregulation of BACE activity. [34] [35] [36] Additionally, cerebral ischemia has been associated with increased production of Ab from APP, both in experimental models 37, 38 and in humans. [39] [40] [41] These reports suggest a link between energy metabolic disturbance and Ab peptide formation.
Experimentally, Ab may also have direct neurotoxic properties, [42] [43] [44] and, therefore, be important for the pathophysiology of TBI. In three recent publications, 25, 26, 45 MD was used to detect interstitial Ab formation early following severe TBI in humans. Using an Ab(1-x) enzyme-linked immunosorbent assay (ELISA) not directly measuring Ab40 or Ab42, MD-Ab levels were found to correlate with the level of consciousness in neurovascular and TBI patients in an NCC setting. 26 In another report, the temporal patterns of Ab peptides could be studied in 12 h fractions using a sandwich ELISA. 25 The results of this pilot study showed that Ab42 was consistently higher in patients with diffuse TBI, calling for additional studies of this potentially useful biomarker of diffuse axonal injury (DAI). However, the sensitivity of the assay was limited. In the present report, we used the Luminex technique to improve the analytical sensitivity to enhance the temporal resolution of Ab peptide dynamics in 10 patients with moderate to severe TBI. Our main hypotheses were that Ab peptide levels would correlate with the presence of diffuse brain injury, indicating axonal injury, cerebral energy metabolic perturbation, patient age, and the level of consciousness.
Methods
All research procedures described herein were approved by the Regional Research Ethics Committee at Uppsala University and informed consent was obtained from the patient's closest relative.
This single center study was performed in a university hospital NCC setting.
Patient population and neurocritical care management
We included 10 patients (7 male, 3 female) conveniently recruited with a severe TBI, defined as a post-resuscitation Glasgow Coma Scale (GCS) score £ 8 at the primary hospital. On arrival in our unit, all patients were intubated and the motor component of the GCS (the Glasgow Motor Scale [GMS] ) is presented in Table 1 . No patient had a previous history of a neurodegenerative disease or Down's syndrome. All patients required treatment in a NCC setting, including intubation and mechanical ventilation, and were managed according to a standardized brain injury protocol aiming to keep intracranial pressure (ICP) at £ 20 and cerebral perfusion pressure (CPP) at ‡ 60 mm Hg. 46, 47 ICP was monitored in all patients, either with an intraparenchymal ICP monitor (Codman, Johnson & Johnson, six patients), an external ventricular drain (three patients) or both (one patient). We used a sedation protocol in which patients were sedated using continuous intravenous propofol infusion (1-4 mg/kg/h Propofol-Lipuro; B. Braun Melsungen AG, Melsungen, Germany) combined with intermittent intravenous morphine (1-3 mg Morfin Meda; Meda, Sollentuna, Sweden). When ICP elevations could not be controlled using standard therapy, continuous sodium pentobarbital infusion therapy was initiated in one patient. Volume substitution and/or inotropic agents (Dobutamine or norepinephrine) were administered when needed. Plasma glucose was frequently evaluated and maintained at 5-10 mmol/L where insulin was administered when plasma glucose levels reached > 10 mmol/L. A neurological examination was performed regularly, up to six times daily, using the neurological wake-up test to register the motor component of the GCS (the GMS) and focal neurological signs on computerized observation charts. 46 For presentation of data, the patients were classified into conscious (GMS = 6) or not (GMS < 6) during the time for Ab sampling (described subsequently). Additional injuries were scored according to the New Injury Severity Score (NISS), ranging from 1 to 75. 48 At *6 months post-injury, patient outcome was assessed using the extended Glasgow Outcome Scale (eGOS 49 ).
Radiological analysis
CT scans were frequently performed as part of the monitoring strategy. When analyzing each CT scan, the ''worst'' CT scan (i.e., Number of hours post-injury at which the microdialysis was initiated and stopped; the interval between the numbers represents the total duration of microdialysis.
DAI, diffuse axonal injury; eGOS, extended Glasgow Outcome Scale at 6 months post-injury; GMS, motor component of the Glasgow Coma Scale; NISS, New Injury Severity Score; LOS, length of stay; MD, microdialysis; MVA, motor vehicle accident.
the CT scan with the most intracranial lesions and/or mass effect during the course of the disease) was selected and analyzed for each of the 10 patients. 50 We used the Marshall classification 51 and divided the patients into having either a DAI or a focal/mixed TBI. 25 Radiological characteristics of focal/mixed TBI included focal lesions such as epi-and subdural hemorrhages and lobar contusions. Criteria for DAI were diffuse brain swelling and/or small petechial hemorrhages located at the gray/white matter junction, corpus callosum, and/or brainstem. Compression of basal cisterns was determined by the following scoring system: 0 = normal, 1 = compressed yet visible, 2 = compressed. The midline shift was calculated at the level of the thalami. The volume in milliliters of each mass lesion was calculated using the formula length · width · height/2.
MD procedure
The MD probe was inserted in conjunction with implantation of the ICP monitoring device, typically in the nondominant frontal lobe 1-2 cm anterior to the coronal suture (n = 7) or at the craniotomy site after evacuation of a focal mass lesion (n = 3). Care was taken to insert the MD catheter obliquely into the cortex using a non-traumatic technique. 25 We used 71 High Cut-Off Brain MD catheters with a membrane length of 10 mm and a 100 kDa nominal molecular weight cutoff polyarylethersulfone (PAES) membrane (M Dialysis AB, Solna, Sweden). The outflow hydrostatic pressure of the perfusion system was set at the zero midcranial reference level by taping the collecting vials at the bandage on the patient's head to avoid additional hydrostatic effects on fluid recovery of the catheter. Perfusion of the catheters was performed using artificial cerebrospinal fluid (CSF) (Perfusion Fluid CNS, M Dialysis), containing NaCl 147 mM, KCl 2.7 mM, CaCl 2 1.2 mM, and MgCl 2 0.85 mM with the addition of 1.5% human serum albumin, 26 at a rate of 0.3 lL/ min using a 106 MD pump (M Dialysis). At least 2 h passed after insertion of the MD catheter and start of sampling to allow for normalization of changes caused by catheter insertion. MD vials (*18 lL samples) were changed hourly. Samples were analyzed at the bedside using CMA microdialysis analyzers (CMA600 and ISCUSflex; M Dialysis) for concentrations of glucose (MD-glc), lactate (MD-lac), and pyruvate (MD-pyr), and the LPR was calculated. Glutamate (MD-glut) and glycerol (MD-glyc) were analyzed later (CMA600). Urea was monitored to control the MD catheter performance. 52 The remaining samples were stored at -70°C until further analyzed for Ab peptides (described subsequently). The CMA 600 Analyser was automatically calibrated when started, as well as every 6th h using standard calibration solutions from the manufacturer (M Dialysis). Quality controls at two different concentrations for each substance were performed every weekday (CMA600 and ISCUSflex). The correlation between CMA600 and ISCUSflex data from separate runs with the same control sample was found to be excellent (for all analytes used here r was ‡ 0.99) allowing for direct comparison of patient data from both instruments. Imprecision values for between assay coefficient of variation was < 10% for all analytes. The location of the MD catheter was evaluated on follow-up CT scans in all patients and checked for hemorrhages. The presence of any hemorrhage visible on TBI within 3 cm of the MD probe was analyzed on all CT scans and noted in Table 2 .
Based on previous data, 53, 54 the following values for the routine biomarkers were considered critical:
Analysis of Ab peptides
After bedside analysis, the remaining hourly microdialysis samples (*14 lL) were pooled into 2 h fractions. Ab42 and Ab40 levels were measured using the INNO-BIA Ab forms assay (Innogenetics, Ghent, Belgium), which is a multiplex microspherebased Luminex xMAP technique. In this assay, the monoclonal antibodies 21F12 and 2G3, which specifically bind Ab peptides ending at Ala42 and Val40, respectively, were used as capture antibodies, and the monoclonal antibody 3D6, which specifically binds Ab peptides starting at Asp1, was used as detector antibody. 55 All samples were analyzed in the presence of a mild detergent in the kit, which makes most of the Ab accessible to the antibodies, although without using denaturing extraction protocols. Because of the small sample volume available, all samples were diluted 15-fold before analysis. The lowest standard point was 15 pg/mL for Ab40 and 5 pg/mL for Ab42. The lowest reported levels were set to half the value of the lowest standard point, which after correction for dilution gives a cutoff of 112 pg/mL for Ab40 and 37 pg/ mL for Ab42. All analyses were performed by experienced and board-certified laboratory technicians. Serial samples from the same patient were analyszd on the same plate. Intra-and inter-plate coefficients of variation were below 10%. 
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Statistical analysis
The microdialysis data was analyzed using the one sample Kolmogorov-Smirnov test and was found not to meet the assumption of normal distribution ( p < 0.05 for all analytes). Therefore, pairwise comparisons between groups were analyzed using the Mann-Whitney U test (Statistica software; StatSoft, Tulsa, OK). Nonparametric data are presented as medians and 75th percentile or individual values, whereas parametric data are presented using the means -standard deviations (SD). Correlation analysis was performed on the first 48 h MD samples using Spearman's rank correlation. For area under the curve (AUC) calculations, we focused our analysis on the initial 19-146 h (day 1-6) post-injury. A p value < 0.05 was considered statistically significant.
Results

Patient characteristics and radiology
The mean age of the patients was 38.5 -18 years (range 18-76 years). The median GMS score on arrival in our NCC unit was 4 (range 2-6). Additional clinical characteristics including the NISS score are presented in Table 1 . Based on the Marshall classification, the patients were divided into two groups: focal/mixed and DAI (Table 2) . Five patients were categorized as having a DAI and five were categorized as having a focal/mixed injury. Radiological characteristics of each patient are presented in Table 2 . Focal mass lesions were surgically evacuated in three patients (1, 4, and 7; Table 2 ).
Microdialysis procedure
The mean duration from time of accident to start of MD sampling was 19.7 h (range 7-75 h), and the mean duration was 179.9 -81 h (range 45-329 h; Table 1 ). Probe function was monitored using MD-urea levels, which were found to be stable, thus indicating adequate probe function, with a gradually increasing trend during the course of the monitoring period as previously shown. 52 Less than one percent of urea samples showed deviating levels from the expected trend, leading to exclusion of all MD data during that hour. No signs of hemorrhage around the MD probe were seen on any of the control CT scans.
Interstitial Ab40 and Ab42 levels
We were able to detect Ab40 and Ab42 in 2 h MD samples for all 10 patients using the Luminex method. 55 In total, 1530 MD samples were analyzed for both markers (n = 765 samples for each marker).
All together, the interstitial Ab40 and Ab42 levels were only slightly variable, with minor fluctuations during the course of the disease (Fig. 1A and B) . We hypothesized that the Ab levels were related to injury type, energy metabolic situation, age of the patient, and/or the level of consciousness.
First, we compared the Ab peptide levels in relation to injury type (Fig. 1A-D) .
Including all MD samples, the median interstitial Aß40 levels were 782 pg/mL (range 457.0-971.3 pg/mL) and 436 pg/mL (range 281.3-766.5 pg/mL) in the DAI and focal TBI groups, respectively. Ab42 levels were 106 pg/mL (range 62-127.5 pg/mL) and 60 pg/ mL (range 46-90 pg/mL) in the DAI and focal TBI group, respectively. The Ab peptide levels were consistently higher in the patients with DAI than in patients with a focal TBI, being statistically significant for Ab42 at 113-116 h post-injury ( p < 0.05; Fig.  1A and B) . Area under the curve (AUC), calculated from 19-146 h post-injury, was also compared (Fig. 1C and D) . The AUC in the DAI group tended to be higher than the total AUC in the focal injury group (Fig. 1C and D) , although without reaching statistical significance. For all samples, there was a strong correlation between interstitial Aß40 and Ab42 levels (r = 0.987; Fig. 1E ) and no association of the Ab42/Ab40 ratio with any of the outcome parameters was observed (data not shown).
We hypothesized that the energy metabolic situation could influence Ab levels, and we performed a correlation analysis between the low molecular weight (LMW) biomarkers and Aß-peptide levels (Fig. 2 A-D) . However, Ab levels only weakly correlated with the evaluated biomarkers for cerebral ischemia (shown for the LPR (r = 0.40 and r = 0.41 for Aß40 and Ab42, respectively; p < 0.05) in Fig. 2 A and B, MD- Fig. 6A ) without other significant differences in energy metabolic markers depending upon injury type or age of the patient. We then evaluated the influence of age on Ab levels, divided into two groups ( < 40 and > 40 years old). Age did not significantly influence our Ab peptide results (Fig 3A-D) . There was no correlation between the clinical outcome evaluated using the extended Glasgow coma outcome scale (eGOS) and the Ab peptide levels (data not shown).
Five patients never obeyed command during the monitoring time (deemed unconscious) evaluated by the neurological wake-up test, five did (deemed conscious), and we next analyzed the effect of level of consciousness on Ab peptide levels. 26 The levels of Ab40 and Ab42 were not significantly influenced by the level of consciousness (Fig. 4A-D) nor was there a correlation between Ab and LPR or MD-glc (data not shown). Additionally, the frequent neurological wake-up tests did not markedly alter Ab40 and Ab42 levels (for an illustrative patient example see Fig. 5 ). In most patients, there were only slight fluctuations in Ab40 and Ab42 levels. One patient in the DAI group (case 8, Fig. 4 ) had very high Ab levels (Fig. 5) .
Analyses of low-molecular weight MD markers LPR. A total of 1582 MD samples could be analyzed for the LPR. LPR levels were significantly higher early post-injury in the focal injury group (Fig. 6A) . Age (Fig. 6B ) and the level of consciousness (data not shown) did not influence the LPR levels.
MD-glc.
A total of 1582 MD samples were analyzed for glucose (MD-glc). Of these, 179 samples (11.3%) had a critical MDglc value of < 1 mmol/L. Injury type (Fig. 6A), age (Fig. 6B) , and level of consciousness (data not shown) did not significantly influence MD-glc levels.
MD-glut.
We could analyze 1302 samples for glutamate (MDglut). The MD-glut values did not markedly differ between the injury groups (Fig. 6A ) and was not influenced by the level of consciousness (data not shown). In young patients, MD-glut levels were consistently higher mainly because of one young patient with high MD-glut levels (Fig. 6B ). 8/12 samples from 111 to 123 h post-injury; Fig. 6A ). Age (Fig. 6B) or the level of consciousness (data not shown) did not significantly influence the MD-glyc levels.
Discussion
The aim of this study was to evaluate the dynamics of the Ab peptides Ab40 and Ab42 after TBI using intracerebral MD. The refined analysis method allowed for monitoring of both Ab40 and Ab42 in 2 h fractions in a small but thoroughly characterized TBI cohort. These results provide a unique data set for evaluation of Ab peptide dynamics in the acute phase following injury, with higher temporal resolution and analytical specificity than in previously published studies. 25, 26, 45 The Ab results were also compared with injury type, biomarkers for cerebral energy metabolism (glucose, lactate, pyruvate), cellular distress (glycerol, and glutamate), and clinical factors including patient age and level of consciousness, to test our main hypotheses. Higher Ab levels in patients with diffuse brain injury compared with focal TBI were observed, supporting our previous data suggesting that Ab peptides may be valuable biomarkers for axonal injury. 25 In contrast, the energy metabolic situation evaluated using MD biomarkers of ischemia and cellular distress in the same brain region only weakly correlated with Ab peptide levels. Additionally, patient age or level of consciousness did not clearly influence Ab levels in this patient cohort.
We observed that the levels of the Ab peptides Ab40 and Ab42 were higher in patients with diffuse brain injury than in those with focal TBI, and there are several lines of evidence suggesting an increased Ab formation following diffuse TBI. First, in approximately one third of TBI patients, Ab plaques have been detected in the postmortem brain, 56 in surgically resected tissue, 11, 12 and in injured axons of DAI patients dying < 9 days post-injury.
14 This TBI-induced Ab pathology can remain for many years in the brains of TBI survivors. 5, 57 Second, following diffuse TBI in the pig, Ab plaques were observed in the one third of animals displaying the most severe axonal injury. 58 Importantly, such plaques occur not only in cortical tissue but also in white matter tracts. 14 Finally, axonal accumulation of Ab, APP, and BACE has been observed in both human and pig DAI up to 3 years post-injury. 21, 22, 59 Therefore, it appears likely that a prolonged APP accumulation in swollen axons results in an increased formation of Ab peptides 5, 56, 60 released into the interstitial compartment following axonal rupture.
It should be noted that the classification of focal TBI versus DAI was solely based on the Marshall classification of CT scans, which is based on a 1991 analysis of the Traumatic Coma Data Bank. Although this classification was found to be predictive of a poor outcome, its ability to predict detailed neuropsychological deficits has not been established. 61 MRI is clearly more sensitive than CT for small lesions such as those observed in DAI patients. 62 In our material, no patient in the DAI group had a focal lesion, and the largest hematoma in this group was < 4mL. However, with ever increasing sensitivity of MRI, it is becoming clear that a high proportion of patients with predominately focal TBI display components of axonal injury. 63 As standard CT and MRI may underestimate the extent of white matter damage after TBI, 64, 65 additional neuroradiological tools such as diffusion tensor imaging (DTI) could further increase the detection of white matter damage post-injury. 66 Ideally, MR scans following the implantation of the MD catheters could in more detail have evaluated the details of axonal injury in the vicinity of the probes in our present study.
The Ab40 and Ab42 levels did not markedly fluctuate during the initial post-injury days following human TBI, in contrast to previous MD studies in which they gradually rose over time. 26, 45 Our observations are also in contrast to experimental data analyzing Ab levels using MD early following focal TBI in mice. In awake, moving mice, the hippocampal Ab levels declined by up to 50% post-injury, depending upon injury severity. In animals with severe TBI, the Ab decline was more marked and prolonged than in animals with a milder, focal TBI. 67 In the present series, the pre-injury levels were unknown, and initial Ab levels may have been different. It is likely that human TBI represents a less marked focal TBI than what is used in the rodent model, 68 making direct comparisons difficult. Although the evidence cited in the previous paragraphs suggest that Ab levels may be increased post-injury, we must also consider that the Ab levels presented in our study may actually be reduced in some TBI patients. 45 In a previous study, patients with contusions had lower Ab peptide levels than did DAI patients, 26, 45 findings similar to our present and previous report. 25 In our focal TBI group, three patients had their MD probes close to an evacuated mass lesion, and the lower values observed in the focal TBI group may also represent reduced levels in the vicinity of contusion caused by Ab consumption in the formation of plaques. Although the lack of histology makes any explanation hypothetical, early plaque formation is observed in only one third of TBI patients (see earlier description). Therefore, it is unlikely that the reduced Ab levels in focal TBI patients are the result of plaque formation. Although CSF Ab concentration may differ from the interstitial concentration, 5 levels of Ab42 have been reported to increase following TBI. 60, [69] [70] [71] [72] Any biomarker may also have an effect on the injury process itself. Based on experimental data, interstitial Ab may have deleterious effects following TBI. 24 Neurotoxic and synaptotoxic effects of Ab oligomers per se have also been observed. [42] [43] [44] Therefore, the interstitial Ab could influence the secondary injury cascade after TBI. In addition, alternate splicing of the APP molecule may occur, and generation of other Ab species than Ab42 evaluated in our present report is possible. The shorter Ab1-40 (Ab40) makes *80-90% of all generated Ab peptides, although Ab42 is more hydrophobic and prone to aggregate into plaques. 26 In 
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the pathophysiology of TBI, other Ab subspecies than Ab42 may be of interest, which could be evaluated using MD. 73 The cutoff for the MD catheter used in the present study was 100 kDa, and although the molecular weight of Ab42 is *4.5 kD, longer peptides resulting from APP splicing or Ab oligomerization, presumably a key event in the pathogenesis of AD, may not be detected using MD. 74 As cerebral ischemia may influence Ab levels, [34] [35] [36] we evaluated biomarkers for energy metabolic perturbation obtained in the same location and brain compartment as Ab. In contrast to a previous report, 26 which found a positive correlation between MD-Ab and MD-glc and a negative correlation with LPR, we observed only weak correlations. In our series, pathological LPR and/or MD-glc values were rather infrequent and, at least for MD-glc, appeared less frequently than in the study by Brody and associates. 26 Additionally, in that report, six patients with subarachnoid hemorrhage (SAH) were included, and it cannot be excluded that those patients had a different neurochemical profile. The patients in our series had a severe TBI requiring sedation and controlled ventilation. Despite the injury severity, ICP problems were rare, which likely prevented marked neurometabolic perturbation of the brain. It cannot be excluded that another injury severity may have caused a different correlation between Ab peptide levels and the focal neurochemistry.
Previously, currently available ELISA methods were considered too insensitive to enable measurement of Ab 1-42 levels, and in a previous report, an ELISA evaluating Ab species from amino acid 1-28 or greater (Ab1 -x) was used. 26 When using that analysis, the majority of the Ab was neither Ab40 nor Ab42, and it was suggested that Ab40 and Ab42 concentrations were lower than the Ab1 -x concentrations by a factor of 35 and 2.5, respectively. 26 In our previous study, a high sensitivity variant of a commercially available ELISA kit was used. 25 In 12 h pooled samples, we were able to analyze Ab40 in *50% of the patients, and were able to analyze Ab42 in seven out of eight patients. These levels were comparable to those obtained in the present report. However, in the present report, the analysis of Ab40 and Ab42 in 2 h samples was possible in all patients, indicating a superior sensitivity using the microsphere-based Luminex xMAP technique. The high specificity of the antibodies used in the present report and their application in the Luminex technique has previously been established. [75] [76] [77] As long-term storage of CSF and plasma samples was found to influence the analysis of Ab, 78, 79 consideration of pre-analytical factors was crucial. Prior to analysis, the MD samples in our present study were stored at -70°C, and every precaution was taken to handle and store the samples properly. We believe that the minor fluctuations of Ab during the course of the disease for the individual patient reflected this effort. In addition, the MD membrane may serve as a barrier separating Ab from degrading enzymes such as insulysin and neprilysin, 80 contributing to sample stability. Finally, other groups have observed long-term stability of Ab in CSF samples for > 2 years of freezing, 81, 82 arguing that pre-analytical factors did not markedly influence our results. However, further studies are clearly needed to define the effect of pre-analytical factors such as long-term storage on analyte levels.
Although astrocytes, microglia, and endothelial and smooth muscle cells may release Ab, neurons express the highest levels of APP and may release Ab into the extracellular space under normal cellular conditions. 83 In one previous report using MD, the Ab levels were dependent on the level of consciousness. 26 In that report, studying a mixed TBI and SAH cohort, Ab levels rose when the patient's neurological status improved and vice versa. Here, we did not detect a similar correlation among Ab40, Ab42, and the level of consciousness in a pure TBI cohort. As an important part of routine NCC monitoring, we frequently evaluate the neurological status (the motor component of the GCS), using the neurological wake-up test 46 requiring that the continuous sedation be interrupted. Despite the absence of sedation during the tests, interstitial Ab levels were not markedly altered. There are several experimental reports suggesting a link between extracellular Ab dynamics and neuronal activity. [83] [84] [85] [86] It is plausible that TBI-induced factors are responsible for regulating neuronal activity and, conversely, Ab levels. The wake-up test and reduction of sedation may not be sufficient to overcome TBI-induced depression of neuronal activity. In addition, the neurological evaluation performed in the NCC setting provides only a crude measurement of neuronal activity, and may be influenced by many additional factors other thanTBI severity. Therefore, the lack of correlation between Ab levels measured using MD and the level of consciousness observed here may not be surprising. However, as there was a lack of pre-injury, baseline Ab levels in the present data cannot resolve the possibility that our findings were the result of increased Ab caused by axonal injury or a larger decrease in Ab levels in focal TBI caused by a more marked regional decrease in neuronal activity. In addition, Ab oligomers and protofibrils could be elevated after TBI, despite a reduction in MD Ab levels. These issues should be addressed in future studies.
Limitations
There are obvious limitations to our study. The present cohort of 10 TBI patients is small, which may have prevented us from detecting significant correlations between Ab levels and a number of clinical and radiological factors. Because of the heterogeneity of TBI, this number may be insufficient to enable firm conclusions, and even though each patient was thoroughly characterized, additional studies are needed. A routine use of MR imaging would more accurately have been able to determine the pathology and presence of axonal injury in the vicinity of the MD probe. Additionally, multimodal monitoring of each patient including electroencephalogram (EEG) and brain tissue oxygenation combined with, for example, positron emission tomography (PET) monitoring could have strengthened the interpretation of energy metabolic changes in relation to MD Ab levels. The Ab peptides evaluated in the present report may be relevant in the acute pathophysiology of TBI, and recent studies have indicated the importance of Ab oligomers, not measured in the present study, in neurodegeneration. 87 Even though Ab is produced by normal neuronal metabolism, 88 the normal extracellullar Ab levels using MD and our present analysis technique are unknown. Finally, the rates of enzymatic degradation, uptake into activated microglia, and receptor-mediated export of Ab to other organs, 73 perhaps influenced by TBI, were not measured, and may have modulated our MD Ab levels.
Conclusion
Using a microsphere-based Luminex xMAP technique, we were able to analyse and monitor Ab40 and Ab42 levels in bi-hourly samples in severe human TBI. Our data support the notion that MD is a useful tool for studying Ab dynamics following TBI. We also confirm our previous hypothesis that these Ab peptides occur at higher concentration in patients with diffuse injury than in those with focal TBI. However, we could not find a correlation between Ab levels and the focal energy metabolic situation, biomarkers of cellular distress, age of the patient, or the patient's level of consciousness. Future studies using an increased number of TBI patients are needed to confirm these observations. Additional markers such as tau and neurofilament and/or Ab subspecies including oligomers and protofibrils should also be used as previously suggested 73 for elucidating the potential role of Ab in the pathobiology of TBI as well as the complex relationship between TBI and AD pathology.
